Focus on Malignant Pleural Mesothelioma Immunology and Immunotherapy - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Focus on Malignant Pleural Mesothelioma Immunology and Immunotherapy write by Christophe Blanquart. This book was released on 2023-08-15. Focus on Malignant Pleural Mesothelioma Immunology and Immunotherapy available in PDF, EPUB and Kindle. Malignant pleural mesothelioma (MPM) is a rare thoracic cancer that derives from the mesothelial cells of the pleura and is causally associated with exposure to asbestos. Because of its aggressiveness and resistance to therapies, MPM prognosis is extremely poor and the 5-year survival rate is approximately 10%. Despite its poor effectiveness, chemotherapy with cisplatin and pemetrexed has long remained the standard-of-care for upfront treatment with no second line therapy available. Recently, the approval of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) for the first-line treatment of unresectable MPM has marked a significant milestone, in particular for the non-epithelioid MPM subtype, which is more resistant to chemotherapy and associated with a poorer outcome. However, most MPM patients are still resistant to cancer therapies. Beyond histologic subtypes, recent studies have highlighted extensive genetic variation and gene expression deregulation both between and within MPM patients. This molecular heterogeneity highlights the need for a personalized treatment approach. Therefore, both multiple therapeutic options and predictive biomarkers that can guide clinical decision-making are urgently needed. Tumor cell immunogenicity and tumor microenvironment composition (TME) are the major determinants of the success of immunotherapy. Despite the low tumor mutational burden, recent studies indicate that chromoanagenesis and chromotripsis are molecular features of MPM. Since chromosomal instability can lead to the expression of neo-antigens, it could also influence the efficacy of immune checkpoint inhibitors (ICIs). The immunosuppressive TME is an additional important hurdle that limits the efficacy of immunotherapy. The combination of ICIs with strategies to boost anti-tumor immunity by restraining immunosuppressive myeloid cells or by reprograming “cold tumor” into “hot tumor” is an active area of research. This Research Topic aims to discuss recent advances in understanding and targeting MPM immune microenvironment for therapeutic purposes along with potential predictive biomarkers to select patients who most likely will respond to immunotherapies. We are interested in basic and clinical studies that explore the crosstalk between tumor and immune cells in order to highlight new molecular targets, approaches, and combination treatments to enhance anti-tumor immunity in MPM and assess potential predictive biomarkers of response to immunotherapy.
Malignant Pleural Mesothelioma
Malignant Pleural Mesothelioma - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Malignant Pleural Mesothelioma write by Takashi Nakano. This book was released on 2021-02-05. Malignant Pleural Mesothelioma available in PDF, EPUB and Kindle. This book provides essential information on recent advances in molecular genetics, epidemiology, translational research, and the latest results of clinical trials on mesothelioma. Significant progress has been made in understanding mesothelioma biology, and in developing new therapies for this refractory tumor, malignant pleural mesothelioma (MPM). Not only does this volume summarize the latest research-based data on the disease; it also shares insights into future research directions. The book consists of 5 themed sections on: epidemiology, pathogenesis, screening and early detection, molecular genetics, and clinical aspects and management. Several chapters focus on new trends in the field, e.g. immune therapy and identification of biomarkers, molecular oncogenesis including genetic susceptibility, and molecular diagnostic pathology. The book also highlights new cancer treatment approaches, such as immunotherapy based on immune checkpoint inhibitors, which has meant a paradigm shift in other types of cancer, and given some hope to MPM patients. In turn, it discusses recent molecular pathological studies on mesothelioma, which claim to offer more accurate classifications than traditional morphology and immunohistochemistry-based approaches. All of these cutting-edge analyses provide the basis for a closing discussion on future developments and research directions. Malignant Pleural Mesothelioma - Advances in Pathogenesis, Diagnosis, and Treatments has been edited and authored by respected researchers and will be of interest to medical, surgical and radiation oncologists; pulmonologists; pathologists and basic researchers alike. Since the disease represents a significant diagnostic and therapeutic challenge, scientists and clinicians from learners to experts, as well as fellows in training in these subspecialties, will value this book.
Immunotherapy in Malignant Pleural Mesothelioma
Immunotherapy in Malignant Pleural Mesothelioma - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Immunotherapy in Malignant Pleural Mesothelioma write by Nobukazu Fujimoto. This book was released on 2020. Immunotherapy in Malignant Pleural Mesothelioma available in PDF, EPUB and Kindle. Malignant pleural mesothelioma (MPM) is an extremely aggressive plural malignancy mainly caused by asbestos exposure. Basic research about the immune suppressive tumor microenvironment in MPM has suggested that MPM might be a good candidate for immune therapy. Immunocheckpoint inhibitors have shown some promising results. A phase Ib trial with pembrolizumab, an antibody specific for the programmed cell death 1 protein (anti-PD-1), showed efficacy in patients with programmed death-ligand 1 (PD-L1)-positive MPM. Among 25 patients tested, 5 patients (20%) achieved a partial response. A Japanese group evaluated the efficacy and safety of nivolumab, an anti-PD-L1 antibody, for patients with advanced MPM in a phase II study. Ten (29%) patients showed an objective response. Based on those results, nivolumab was approved in Japan for unresectable recurrent MPM. A phase III randomized study was conducted to compare nivolumab plus ipilimumab to platinum doublet chemotherapy as a first-line therapy in unresectable MPM. The primary endpoint, overall survival (OS), was significantly improved in the nivolumab plus ipilimumab group. Cellular therapies and cancer vaccines are limited by many challenges; therefore, improvements to overcome these difficulties are urgently warranted. Further research is needed, including large-scale clinical trials, to clarify the utility and safety of immunotherapy in MPM.
Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma
Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma write by Nobukazu Fujimoto. This book was released on 2022. Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma available in PDF, EPUB and Kindle. Malignant pleural mesothelioma (MPM) is a neoplasm strongly associated with past exposure to asbestos. In general, the prognosis of patients with MPM is poor; however, in recent years, some encouraging results have been reported for systemic therapies for MPM. In a randomized phase III study, the combination of nivolumab and ipilimumab improved overall survival, compared to the standard platinum-based chemotherapy. An important clinical issue is whether the outcome of patients with MPM might be further improved by combining immunotherapies with cytotoxic chemotherapy and/or angiogenesis inhibitors. This chapter covers recent findings on systemic therapies, including cytotoxic chemotherapy, anti-angiogenic inhibitors, and/or immune checkpoint inhibitors.
Mesothelioma
Mesothelioma - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Mesothelioma write by Giovanni Luca Ceresoli. This book was released on 2019-06-19. Mesothelioma available in PDF, EPUB and Kindle. This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease’s biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas – e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials – and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike.
